Annual Report Searches
Alphabetical Search



Lexicon is a fully integrated biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for patients with serious, chronic conditions. Through its Genome5000 program, Lexicon scientists have studied the role and function of nearly 5,000 genes over the last 20 years and have identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. In addition to its first commercial product, XERMELO for carcinoid syndrome diarrhea, Lexicon has a pipeline of promising drug candidates in clinical and pre-clinical development in diabetes and metabolism and neuropathic pain.

Yearly Figures
(in thousands, except per share amounts)
FYE: 12/31 2017 2016 2015 2014
Net Revenues $90,335 $83,337 $130,014 $22,854
Net Income (Loss) ($129,050) ($141,429) ($4,682) ($100,294)
Earnings Per Share (1.23) (1.36) (0.05) (1.31)
Quarterly Figures
(in thousands, except per share amounts)
              Fourth Quarter
FYE: 12/31 12/31/17 12/31/16
Net Revenues $33,047 $23,037
Net Income (Loss) ($28,378) ($32,419)
Earnings Per Share (0.27) (0.31)
Contact Information
Contact Name: Alex Abuin
Contact Title: Vice President, Corporate Communications
Phone: 1-281-863-3000